Ambeed.cn

首页 / / / / Hinokitiol/桧木醇

Hinokitiol/桧木醇 {[allProObj[0].p_purity_real_show]}

货号:A161005 同义名: β-桧木醇 / β-Thujaplicin; NSC 18804

Hinokitiol是一种天然存在的单萜酚,具有抗氧化、抗菌、抗炎和抗肿瘤活性,可调节铁代谢并通过降低 Nrf2 的表达影响 DNA 甲基化相关蛋白的表达。

Hinokitiol/桧木醇 化学结构 CAS号:499-44-5
Hinokitiol/桧木醇 化学结构
CAS号:499-44-5
Hinokitiol/桧木醇 3D分子结构
CAS号:499-44-5
Hinokitiol/桧木醇 化学结构 CAS号:499-44-5
Hinokitiol/桧木醇 3D分子结构 CAS号:499-44-5
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Hinokitiol/桧木醇 纯度/质量文件 产品仅供科研

货号:A161005 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >
产品名称 Ca2+ channel-like protein Calcium Channel Cav 2.2 其他靶点 纯度
CDC25B-IN-2 Akt 99%+
Clevidipine 97%
Verapamil HCl 99%
Amlodipine 99%
Amlodipine maleate 98%
(+)-cis-Diltiazem HCl 99%
Zegocractin ++

Orai1/STIM1-mediated Ca2+ currents, IC50: 120 nM

99%+
Tanshinone IIA sulfonate sodium 98%
Ulixacaltamide ++

hCaV3.1, IC50: 50 nM

hCaV3.2, IC50: 110 nM

99%+
Dronedarone HCl 95%
Nitrendipine +

Calcium channel, IC50: 95 nM

98%
Efonidipine HCl monoethanolate 98%
Cinnarizine 98%
SEA0400 ++

NCX, IC50: 33 nM

ERK,ROS,p38 MAPK 99%+
Fasudil HCl Rho,PKA 98%
ML-9 MLCK,Akt 99%+
Flunarizine 2HCl +

Calcium channel, Ki: 68 nM

95%
Lomerizine 2HCl 98%
Efonidipine 98%
Levamlodipine 98%
Nisoldipine ++

L-type Cav1.2, IC50: 10 nM

97%
Isradipine 98%
Lacidipine 98%
Lercanidipine 99%
Loureirin B Potassium Channel 99%+
Tetracaine HCl 98%
Manidipine +++

Calcium channel, IC50: 2.6 nM

99%
Manidipine Dihydrochlorid +++

Calcium channel, IC50: 2.6 nM

98%
Nicardipine 99%
Wilforgine 98+%
Econazole 99%+
Ginsenoside Rd NF-κB 98%
Fendiline HCl 98+%
Mesaconitine 98%
Tetrandrine 95%
Nifedipine 98%
Nilvadipine ++++

Calcium channel, IC50: 0.03 nM

95%
Barnidipine ++++

[3H]nitrendipine, Ki: 0.21 nM

95+%
Azelnidipine 97%
Levetiracetam 98%
Nimodipine 95%
Benidipine HCl 98%
Pinaverium bromide 98%
Pranidipine 99%
NP118809 +

L-type calcium channel, IC50: 12.2 μM

N-type Ca2+ channel, IC50: 0.11 μM

95%
Amlodipine Besylate +++

Calcium channel, IC50: 1.9 nM

97%
Cilnidipine 99%
Cinepazide Maleate 99% (HPLC)
Terfenadine 98%
YM-58483 99%+
Amiloride HCl 98%
Ranolazine 98%
Praeruptorin A Akt,p38 MAPK 98%
Ranolazine 2HCl 98%
Felodipine ++++

L-type calcium channel, IC50: 0.15 nM

98%
PD173212 +++

N-type Ca2+ channel, IC50: 36 nM

98%
Levamlodipine besylate 97%
Carboxyamidotriazole Orotate 98%
IGS-1.76 98+%
WH-4-023 ++++

Cav 2.2, IC50: 0.001 μM

++++

Cav 2.2, IC50: 0.001 μM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Hinokitiol/桧木醇 生物活性

描述 Hinokitiol, a tropolone-related natural compound, is known to induce apoptosis and cell cycle arrest and has anti-inflammatory and anti-tumor activities. Hinokitiol may exert DNA demethylation by inhibiting the expression of DNMT1 (DNA methyltransferase 1) and UHRF1 (RING finger domain 1) in colon cancer cells[3]. In U87MG and T98G glioma cell lines, hinokitiol demonstrates a dose-dependent decrease in viability, with IC50 values of 316.5 ± 35.5 and 152.5 ± 25.3 µM, respectively. Hinokitiol represses ALDH activity and self-renewal ability in glioma stem cells, and inhibits in vitro oncogenicity. Hinokitiol also reduces Nrf2 expression in glioma stem cells in a dose-dependent manner[4]. Hinokitiol attenuates liver injury following HS/R (Haemorrhagic shock and resuscitation), partly through the inhibition of NF-κB activation[5]. Moreover, hinokitiol inhibited the migration of lung cancer A549 cells through several mechanisms, including the activation of caspases-9 and -3, induction of p53/Bax and antioxidant CAT (antioxidant enzymes catalase) and SOD (superoxide dismutase), and reduction of MMP-2 and -9 (matrix metalloproteinases) activities. It also induces cytochrome c expression[6].

Hinokitiol/桧木醇 细胞实验

Cell Line
Concentration Treated Time Description References
FPN1-deficient J774 macrophages 1 μM Restored iron release in FPN1-deficient cells Science. 2017 May 12;356(6338):608-616
PANC-1 human pancreatic cancer cells 80 μg/mL 10 h To evaluate the effect of Hinokitiol on iron content and mitochondrial function in mammalian cells. Results showed that Hinokitiol had minor effects on iron content and mitochondrial function in mammalian cells, indicating selectivity towards fungal cells. J Adv Res. 2021 Jun 17;34:65-77
BEAS-2B human bronchial epithelial cells 80 μg/mL 10 h To evaluate the effect of Hinokitiol on iron content and mitochondrial function in mammalian cells. Results showed that Hinokitiol had minor effects on iron content and mitochondrial function in mammalian cells, indicating selectivity towards fungal cells. J Adv Res. 2021 Jun 17;34:65-77
Candida albicans SC5314 2-8 μg/mL 30 min to 10 h To evaluate the effect of Hinokitiol on fungal intracellular iron content and its inhibition of mitochondrial respiration. Results showed that Hinokitiol significantly reduced intracellular Fe2+ levels, inhibited the activities of mitochondrial respiratory chain complexes I and II, leading to decreased mitochondrial membrane potential and ATP production. J Adv Res. 2021 Jun 17;34:65-77
Mfrn1-deficient MEL cells 1 μM Restored iron uptake and hemoglobinization in Mfrn1-deficient cells Science. 2017 May 12;356(6338):608-616
DS19 murine erythroleukemia (MEL) cells 1 μM 3 days Restored iron uptake, iron-heme incorporation, and hemoglobinization in DMT1-deficient cells Science. 2017 May 12;356(6338):608-616
Caco-2 gut epithelial cells 500 nM Restored iron uptake and transepithelial iron transport in DMT1-deficient monolayers Science. 2017 May 12;356(6338):608-616
Kupffer cells 5 μM 60 minutes restore iron transport and reduce intracellular iron accumulation Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119
RAW264.7 macrophages 5 μM assess iron release and intracellular labile iron levels Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119
HL-7702 cells 25, 50, 100, 200, 400 nM 24, 48, 72 hours To evaluate the cytotoxicity of β-Thujaplicin on normal liver cells, results showed that β-Thujaplicin had minimal effect on the growth of HL-7702 cells Cell Death Dis. 2019 Mar 15;10(4):255
HCCLM3 cells 25, 50, 100, 200, 400 nM 24, 48, 72 hours To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of HCCLM3 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255
SMMC-7721 cells 25, 50, 100, 200, 400 nM 24, 48, 72 hours To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of SMMC-7721 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255
HepG2 cells 25, 50, 100, 200, 400 nM 24, 48, 72 hours To evaluate the cytotoxicity of β-Thujaplicin on HCC cells, results showed that β-Thujaplicin significantly inhibited the growth of HepG2 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255
CRL-8024 cells 10–100μM To evaluate the effect of hinokitiol on HCC cell proliferation, results showed that hinokitiol significantly attenuated the proliferation of HCC cell lines in a dose-dependent manner while downregulating the protein levels of UHRF1, GLI1, CD44, and CD133. Cell Death Dis. 2023 Jun 28;14(6):381
MEL cells 1 μM probe hemoglobinization and iron uptake Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119
MDA-MB-231 cells 6.25 to 100 µg/mL 48 hours To evaluate anticancer efficacy, results showed that Hinokitiol-loaded phytosomal formulation had higher cytotoxicity than pure Hinokitiol, with an IC50 value of 5.7 µg/mL Int J Nanomedicine. 2024 Oct 12;19:10321-10339
MCF-7 cells 6.25 to 100 µg/mL 48 hours To evaluate anticancer efficacy, results showed that Hinokitiol-loaded phytosomal formulation had higher cytotoxicity than pure Hinokitiol, with an IC50 value of 18.6 µg/mL Int J Nanomedicine. 2024 Oct 12;19:10321-10339
normal liver cell line HL-7702 25, 50, 100, 200, 400 nM 24, 48, 72 h To evaluate the effect of β-Thujaplicin on normal liver cells, results showed that β-Thujaplicin had only a slight effect on the viability of HL-7702 cells at 400 nM Cell Death Dis. 2019 Mar 15;10(4):255.
human hepatoma cell lines HCCLM3 25, 50, 100, 200, 400 nM 24, 48, 72 h To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of HCCLM3 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255.
human hepatoma cell lines SMMC-7721 25, 50, 100, 200, 400 nM 24, 48, 72 h To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of SMMC-7721 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255.
human hepatoma cell lines HepG2 25, 50, 100, 200, 400 nM 24, 48, 72 h To evaluate the inhibitory effect of β-Thujaplicin on HCC cell growth, results showed that β-Thujaplicin significantly inhibited the viability of HepG2, SMMC-7721, and HCCLM3 cells in a dose-dependent manner Cell Death Dis. 2019 Mar 15;10(4):255.

Hinokitiol/桧木醇 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Galleria mellonella Candida albicans-infected larvae Injection 2 μg/larva Single dose, observed for 7 days To evaluate the therapeutic effect of Hinokitiol on Candida albicans infection in vivo. Results showed that Hinokitiol significantly improved the survival rate of infected larvae and reduced fungal burden. J Adv Res. 2021 Jun 17;34:65-77
Belgrade rats DMT1-deficient rat model Oral gavage 1.5 mg/kg Single dose Promoted gut iron absorption in DMT1-deficient rats Science. 2017 May 12;356(6338):608-616
Nude mice HepG2 tumor xenograft model Intraperitoneal injection 5 mg/kg body weight Once daily for 15 days To evaluate the inhibitory effect of β-Thujaplicin on HepG2 tumor growth in vivo, results showed that β-Thujaplicin significantly reduced tumor volume and weight Cell Death Dis. 2019 Mar 15;10(4):255
Mice Myc-driven HCC model Intraperitoneal injection 25 mg/kg Twice a week from 4 to 9 weeks of birth To evaluate the effect of hinokitiol on Myc-driven HCC mouse model, results showed that hinokitiol significantly reduced tumor growth and CSC phenotypes, and downregulated the expression of UHRF1, GLI1, CD44, and CD133. Cell Death Dis. 2023 Jun 28;14(6):381
Mice FPN1-deficient mice Intraperitoneal injection 10 mg/kg Daily for 1 week Restore hemoglobinization and iron distribution Proc Natl Acad Sci U S A. 2022 Jun 28;119(26):e2121400119
Nude mice HepG2 tumor xenograft model Intraperitoneal injection 5 mg/kg body weight Once daily for 15 days To verify the antitumor effect of β-Thujaplicin in vivo, results showed that β-Thujaplicin significantly inhibited the growth of HepG2 tumor xenografts Cell Death Dis. 2019 Mar 15;10(4):255.

Hinokitiol/桧木醇 参考文献

[1]Lee JH, Moon JH, et al. SIRT1, a Class III histone deacetylase, regulates LPS-induced inflammation in human keratinocytes and mediates the anti-inflammatory effects of hinokitiol. J Invest Dermatol. 2017 Feb 28. pii: S0022-202X(17)31149-1.

[2]Seo JS, Choi YH, et al. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017 Feb 27;18(1):14.

[3]Seo JS, Choi YH, Moon JW, Kim HS, Park SH. Hinokitiol induces DNA demethylation via DNMT1 and UHRF1 inhibition in colon cancer cells. BMC Cell Biol. 2017;18(1):14.

[4]Ouyang WC, Liao YW, Chen PN, Lu KH, Yu CC, Hsieh PL. Hinokitiol suppresses cancer stemness and oncogenicity in glioma stem cells by Nrf2 regulation. Cancer Chemother Pharmacol. 2017;80(2):411‐419

[5]Lu WJ, Lin KH, Tseng MF, et al. New therapeutic strategy of hinokitiol in haemorrhagic shock-induced liver injury. J Cell Mol Med. 2019;23(3):1723‐1734

[6]Jayakumar T, Liu CH, Wu GY, et al. Hinokitiol Inhibits Migration of A549 Lung Cancer Cells via Suppression of MMPs and Induction of Antioxidant Enzymes and Apoptosis. Int J Mol Sci. 2018;19(4):939.

Hinokitiol/桧木醇 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.09mL

1.22mL

0.61mL

30.45mL

6.09mL

3.05mL

60.90mL

12.18mL

6.09mL

Hinokitiol/桧木醇 技术信息

CAS号499-44-5
分子式C10H12O2
分子量 164.2
SMILES Code O=C1C(O)=CC(C(C)C)=CC=C1
MDL No. MFCD00040180
别名 β-桧木醇 ;β-Thujaplicin; NSC 18804; 4-Isopropyltropolone
运输蓝冰
InChI Key FUWUEFKEXZQKKA-UHFFFAOYSA-N
Pubchem ID 3611
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry,2-8°C

溶解方案

DMSO: 105 mg/mL(639.46 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
方案 三
配制的工作液建议现用现配,短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。